Company

HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds

Fineline Cube
By
Fineline Cube
3 Min Read
HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds
Summarize with AI

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced 2025 fiscal year results, recording $548.5 million in consolidated total revenue, down 13% year‑over‑year. Despite the decline, key products delivered 5% growth to $524.7 million, with FRUZAQLA (surufatinib) expanding 26% globally on Takeda’s commercialization strength, marking the company’s third consecutive profitable year.

Contents
- Advertisement -

Revenue Performance Summary

Segment2025 RevenueChange (YOY)Key Drivers
Total Revenue$548.5 M–13%Absence of 2024 Takeda milestone; China pricing pressure
Product Sales$524.7 M+5%FRUZAQLA global expansion; H2 China recovery
Oncology Product Revenue$214.4 M–21%$20 M 2024 milestone non‑recurring; NRDL pricing
Other Oncology/Immunology$71.1 M—Milestones, licensing, R&D services
Other Business$263.0 MFlatPrescription drug distribution steady

Product‑Level Performance

ProductMarket2025 SalesChangeStrategic Notes
FRUZAQLA (surufatinib)Global (Takeda)$366.2 M+26%38 countries approved; 15+ launches in 2025 including Portugal, Belgium, South Korea, Mexico
Elunate (surufatinib)China$100.1 M–13%H2 rebound +33% vs. H1; NRDL pricing impact annualized
Orpathys (savolitinib)China——3rd lung cancer indication approved; $11 M milestone from AstraZeneca
SulandaChina——Neuroendocrine tumor franchise stable

Regional Dynamics

RegionTrendCommentary
International (Takeda‑led)Strong growthFRUZAQLA launches in Europe, Asia, Americas accelerating; regulatory momentum in 38 markets
China (HutchMed‑led)H2 inflectionOncology product revenue +23% H2 vs. H1; Elunate volume recovery offsetting price cuts

Pipeline & Visibility Catalysts

AssetStatusRevenue Impact
SovleplenibUnder regulatory reviewPotential 2026 launch for primary ITP
FruquintinibUnder regulatory reviewAdditional indication expansion
FRUZAQLAContinued global rollouts10+ additional markets targeted for 2026
  • Profitability: Third consecutive year of net profitability; operating leverage improving with Takeda‑funded global infrastructure
  • Cash Position: Strong balance sheet supports continued R&D investment and China commercialization

Strategic Outlook

  • Takeda Partnership: Royalty and manufacturing revenue from FRUZAQLA international sales expected to compound at 20%+ CAGR through 2028
  • China Recovery: H2 2025 momentum suggests Elunate/Sulanda franchise stabilization; NRDL price erosion largely absorbed
  • Pipeline Optionality: Sovleplenib approval would diversify revenue beyond oncology into hematology

Forward‑Looking Statements
This brief contains forward‑looking statements regarding product performance, regulatory timelines, and revenue projections for HutchMed. Actual results may differ due to pricing pressures, competitive dynamics, and approval delays.-Fineline Info & Tech

pre260305_FY25Download
pre260305_FY25_scDownload
TAGGED:
Share This Article
Previous Article HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
Next Article Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

You May also Like

CompanyDrug

Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
CompanyDeals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery
CompanyDeals

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine
CompanyDrug

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine

Show More